A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLL

NCT02158091 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG: IPI-145
DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]